시장보고서
상품코드
1193080

유전성 암검사 시장 : 암 유형별, 검사 유형별, 최종사용자별 - 세계 기회 분석 및 산업 예측(2021-2031년)

Hereditary Cancer Testing Market By Cancer Type, By Test Type, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031

발행일: | 리서치사: Allied Market Research | 페이지 정보: 영문 303 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 유전성 암검사 시장은 2021년에 35억 1,029만 달러, 2022-2031년 CAGR 11.6%를 기록하며, 2031년에는 100억 8,749만 달러에 달할 것으로 예측됩니다.

목차

제1장 서론

제2장 주요 요약

제3장 시장의 개요

  • 시장의 정의와 범위
  • 주요 조사 결과
    • 주요 투자 포켓
  • Porter's Five Forces 분석
  • 주요 기업의 포지셔닝
  • 시장 역학
    • 촉진요인
    • 억제요인
    • 기회
  • COVID-19 영향 분석
  • 특허 상황

제4장 유전성 암검사 시장 : 암 유형별

  • 개요
    • 시장 규모 및 예측
  • 유방암
    • 주요 시장 동향, 성장요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 위암
    • 주요 시장 동향, 성장요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 난소암
    • 주요 시장 동향, 성장요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 전립선암
    • 주요 시장 동향, 성장요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 대장암
    • 주요 시장 동향, 성장요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 기타 암
    • 주요 시장 동향, 성장요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별

제5장 유전성 암검사 시장 : 검사 유형별

  • 개요
    • 시장 규모·예측
  • 예측형 검사
    • 주요 시장 동향, 성장요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별 분석
  • 진단 테스트
    • 주요 시장 동향, 성장요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별

제6장 유전성 암검사 시장 : 최종사용자별

  • 개요
    • 시장 규모 및 예측
  • 진단 센터
    • 주요 시장 동향, 성장요인과 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 병원
    • 주요 시장 동향, 성장요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
    • 병원용 유전성 암검사 시장 : 유형별
      • 프라이빗 시장 규모·예측 : 지역별
      • 공적 기관의 시장 규모·예측 : 지역별
  • 진료소
    • 주요 시장 동향, 성장요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별

제7장 유전성 암검사 시장 : 지역별

  • 개요
    • 시장 규모·예측
  • 북미
    • 주요 동향과 기회
    • 북미 시장 규모·예측 : 암 유형별
    • 북미 시장 규모·예측 : 검사 유형별
    • 북미 시장 규모·예측 : 최종사용자별
      • 북미의 병원 유전성 암검사 시장 : 유형별
    • 북미 시장 규모·예측 : 국가별
      • 미국
      • 캐나다
      • 멕시코
  • 유럽
    • 주요 동향과 기회
    • 유럽 시장 규모·예측 : 암 유형별
    • 유럽 시장 규모·예측 : 검사 유형별
    • 유럽 시장 규모·예측 : 최종사용자별
      • 유럽 병원 유전성 암검사 시장 : 유형별
    • 유럽 시장 규모·예측 : 국가별
      • 독일
      • 프랑스
      • 영국
      • 이탈리아
      • 스페인
      • 기타 유럽
  • 아시아태평양
    • 주요 동향과 기회
    • 아시아태평양의 시장 규모·예측 : 암 유형별
    • 아시아태평양의 시장 규모·예측 : 검사 유형별
    • 아시아태평양의 시장 규모·예측 : 최종사용자별
      • 아시아태평양의 병원용 유전성 암검사 시장 : 유형별
    • 아시아태평양의 시장 규모·예측 : 국가별
      • 일본
      • 중국
      • 호주
      • 인도
      • 한국
      • 기타 아시아태평양
  • LAMEA
    • 주요 동향과 기회
    • LAMEA의 시장 규모·예측 : 암 유형별
    • LAMEA의 시장 규모·예측 : 검사 유형별
    • LAMEA의 시장 규모·예측 : 최종사용자별
      • LAMEA 병원 유전성 암검사 시장 : 유형별
    • LAMEA의 시장 규모·예측 : 국가별
      • 브라질
      • 사우디아라비아
      • 남아프리카공화국
      • LAMEA의 기타 지역

제8장 기업 상황

  • 서론
  • 주요 성공 전략
  • 주요 10사의 제품 매핑
  • 경쟁 대시보드
  • 경쟁 히트맵
  • 주요 발전

제9장 기업 개요

  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • CSL Ltd.
  • Danaher Corporation
  • EUROFINS SCIENTIFIC
  • F. HOFFMANN-LA ROCHE LTD
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • Qiagen NV
  • Thermo Fisher Scientific, Inc.
KSA 23.03.15

The global hereditary cancer testing market was valued at $3,510.29 million in 2021, and is projected to reach $10,087.49 million by 2031, registering a CAGR of 11.6% from 2022 to 2031.

Genetic testing helps estimate the chance of developing cancer in the lifetime. This can be done by searching for specific changes in the genes, chromosomes, or proteins  called mutations. Genetic tests are available for some types of cancer which include breast cancer, ovarian cancer, colon cancer, prostate cancer, pancreatic cancer, kidney cancer and stomach cancer. People who are concerned about whether their family history puts them at risk for cancer should consult with a genetic counselor. The features of personal or family medical history of a person that particularly is in combination, may suggest a hereditary cancer syndrome such as the cancer was diagnosed at an unusually young age or several different types of cancer occurred in the same person. Moreover, hereditary cancer testing can also verify the type of cancer inherited in the person. If a person in the family has already been found to have an inherited cancer susceptibility syndrome, then any family members who could have inherited the variant should consider genetic testing. It is because knowing about the risks may help to prevent a future cancer.

The growth of the hereditary cancer testing market is driven by rise in geriatric population and increase in incidence of cancer across the globe, and surge in the government expenditure on healthcare. Moreover, increase in awareness regarding the hereditary cancer testing and favorable reimbursement policies contribute toward the growth of the market. However, lack of skilled professionals and high cost of the tests are expected to hinder the growth of the market. Conversely, high growth potential in untapped emerging economies is expected to create lucrative opportunities for the market.

The hereditary cancer testing market is segmented on the basis of cancer type, test type, end user, and region. On the basis of cancer type, the market is categorized into breast cancer, gastric cancer, ovarian cancer, prostate cancer, colorectal cancer, other cancers. On the basis of test type, the market is classified into predictive testing and diagnostic testing. On the basis of end user, the market is classified into diagnostic centers, hospitals and clinics. Furthermore, the hospitals segment is sub-classified by type as private and public. On the basis of region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include Abbott Laboratories, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Eurofins Scientific SE, F. Hoffmann-La Roche AG, Illumina, Inc., Myriad Genetics, Inc., Qiagen N.V., Thermo Fisher Scientific, Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hereditary cancer testing market analysis from 2021 to 2031 to identify the prevailing hereditary cancer testing market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the hereditary cancer testing market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global hereditary cancer testing market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Cancer Type

  • Breast Cancer
  • Gastric Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Other Cancers

By Test Type

  • Predictive Testing
  • Diagnostic Testing

By End User

  • Diagnostic Centers
  • Hospitals
    • Type
    • Private
    • Public
  • Clinics

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest Of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest Of LAMEA
  • Key Market Players
    • Abbott Laboratories
    • Bio-Rad Laboratories, Inc.
    • CSL Ltd.
    • Danaher Corporation
    • EUROFINS SCIENTIFIC
    • F. HOFFMANN-LA ROCHE LTD
    • Illumina, Inc.
    • Myriad Genetics, Inc.
    • Qiagen NV
    • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market
  • 3.7.Patent Landscape

CHAPTER 4: HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Breast Cancer
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Gastric Cancer
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Ovarian Cancer
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country
  • 4.5 Prostate Cancer
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market analysis by country
  • 4.6 Colorectal Cancer
    • 4.6.1 Key market trends, growth factors and opportunities
    • 4.6.2 Market size and forecast, by region
    • 4.6.3 Market analysis by country
  • 4.7 Other Cancers
    • 4.7.1 Key market trends, growth factors and opportunities
    • 4.7.2 Market size and forecast, by region
    • 4.7.3 Market analysis by country

CHAPTER 5: HEREDITARY CANCER TESTING MARKET, BY TEST TYPE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Predictive Testing
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Diagnostic Testing
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country

CHAPTER 6: HEREDITARY CANCER TESTING MARKET, BY END USER

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Diagnostic Centers
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Hospitals
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
    • 6.3.4 Hospitals Hereditary Cancer Testing Market by Type
      • 6.3.4.1 Private Market size and forecast, by region
      • 6.3.4.2 Public Market size and forecast, by region
  • 6.4 Clinics
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: HEREDITARY CANCER TESTING MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Cancer Type
    • 7.2.3 North America Market size and forecast, by Test Type
    • 7.2.4 North America Market size and forecast, by End User
      • 7.2.4.1 North America Hospitals Hereditary Cancer Testing Market by Type
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Cancer Type
      • 7.2.5.1.2 Market size and forecast, by Test Type
      • 7.2.5.1.3 Market size and forecast, by End User
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Cancer Type
      • 7.2.5.2.2 Market size and forecast, by Test Type
      • 7.2.5.2.3 Market size and forecast, by End User
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Cancer Type
      • 7.2.5.3.2 Market size and forecast, by Test Type
      • 7.2.5.3.3 Market size and forecast, by End User
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Cancer Type
    • 7.3.3 Europe Market size and forecast, by Test Type
    • 7.3.4 Europe Market size and forecast, by End User
      • 7.3.4.1 Europe Hospitals Hereditary Cancer Testing Market by Type
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Cancer Type
      • 7.3.5.1.2 Market size and forecast, by Test Type
      • 7.3.5.1.3 Market size and forecast, by End User
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Cancer Type
      • 7.3.5.2.2 Market size and forecast, by Test Type
      • 7.3.5.2.3 Market size and forecast, by End User
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Cancer Type
      • 7.3.5.3.2 Market size and forecast, by Test Type
      • 7.3.5.3.3 Market size and forecast, by End User
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Cancer Type
      • 7.3.5.4.2 Market size and forecast, by Test Type
      • 7.3.5.4.3 Market size and forecast, by End User
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Cancer Type
      • 7.3.5.5.2 Market size and forecast, by Test Type
      • 7.3.5.5.3 Market size and forecast, by End User
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Cancer Type
      • 7.3.5.6.2 Market size and forecast, by Test Type
      • 7.3.5.6.3 Market size and forecast, by End User
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Cancer Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Test Type
    • 7.4.4 Asia-Pacific Market size and forecast, by End User
      • 7.4.4.1 Asia-Pacific Hospitals Hereditary Cancer Testing Market by Type
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Cancer Type
      • 7.4.5.1.2 Market size and forecast, by Test Type
      • 7.4.5.1.3 Market size and forecast, by End User
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Cancer Type
      • 7.4.5.2.2 Market size and forecast, by Test Type
      • 7.4.5.2.3 Market size and forecast, by End User
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Market size and forecast, by Cancer Type
      • 7.4.5.3.2 Market size and forecast, by Test Type
      • 7.4.5.3.3 Market size and forecast, by End User
      • 7.4.5.4 India
      • 7.4.5.4.1 Market size and forecast, by Cancer Type
      • 7.4.5.4.2 Market size and forecast, by Test Type
      • 7.4.5.4.3 Market size and forecast, by End User
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Cancer Type
      • 7.4.5.5.2 Market size and forecast, by Test Type
      • 7.4.5.5.3 Market size and forecast, by End User
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Cancer Type
      • 7.4.5.6.2 Market size and forecast, by Test Type
      • 7.4.5.6.3 Market size and forecast, by End User
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Cancer Type
    • 7.5.3 LAMEA Market size and forecast, by Test Type
    • 7.5.4 LAMEA Market size and forecast, by End User
      • 7.5.4.1 LAMEA Hospitals Hereditary Cancer Testing Market by Type
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Cancer Type
      • 7.5.5.1.2 Market size and forecast, by Test Type
      • 7.5.5.1.3 Market size and forecast, by End User
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Cancer Type
      • 7.5.5.2.2 Market size and forecast, by Test Type
      • 7.5.5.2.3 Market size and forecast, by End User
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Cancer Type
      • 7.5.5.3.2 Market size and forecast, by Test Type
      • 7.5.5.3.3 Market size and forecast, by End User
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Cancer Type
      • 7.5.5.4.2 Market size and forecast, by Test Type
      • 7.5.5.4.3 Market size and forecast, by End User

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Abbott Laboratories
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Bio-Rad Laboratories, Inc.
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 CSL Ltd.
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Danaher Corporation
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 EUROFINS SCIENTIFIC
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 F. HOFFMANN-LA ROCHE LTD
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Illumina, Inc.
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Myriad Genetics, Inc.
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Qiagen NV
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Thermo Fisher Scientific, Inc.
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제